Domain Specific Changes in Cognition at High Altitude and Its Correlation with Hyperhomocysteinemia

Vijay K. Sharma1, Saroj K. Das1, Priyanka Dhar1, Kalpana B. Hota1, Bidhu B. Mahapatra2, Vivek Vashishtha1, Ashish Kumar1, Sunil K. Hota1*, Tsering Norboo3, Ravi B. Srivastava1

1 Defence Institute of High Altitude Research, Defence Research and Development Organisation, C/o 56 APO, Leh-Ladakh, India, 2 Department of Statistics, Population Council, New Delhi, India, 3 Ladakh Institute of Prevention, Dambuchan, Leh-Ladakh, India

Abstract

Though acute exposure to hypobaric hypoxia is reported to impair cognitive performance, the effects of prolonged exposure on different cognitive domains have been less studied. The present study aimed at investigating the time dependent changes in cognitive performance on prolonged stay at high altitude and its correlation with electroencephalogram (EEG) and plasma homocysteine. The study was conducted on 761 male volunteers of 25–35 years age who had never been to high altitude and baseline data pertaining to domain specific cognitive performance, EEG and homocysteine was acquired at altitude ≅240 m mean sea level (MSL). The volunteers were inducted to an altitude of 4200–4600 m MSL and longitudinal follow-ups were conducted at durations of 03, 12 and 18 months. Neuropsychological assessment was performed for mild cognitive impairment (MCI), attention, information processing rate, visuo-spatial cognition and executive functioning. Total homocysteine (tHcy), vitamin B12 and folic acid were estimated. Mini Mental State Examination (MMSE) showed temporal increase in the percentage prevalence of MCI from 8.17% on 03 months of stay at high altitude to 18.54% on 18 months of stay. Impairment in visuo-spatial executive, attention, delayed recall and procedural memory related cognitive domains were detected following prolonged stay in high altitude. Increase in alpha wave amplitude in the T3, T4 and C3 regions was observed during the follow-ups which was inversely correlated (r = –0.68) to MMSE scores. The tHcy increased proportionately with duration of stay at high altitude and was correlated with MCI. No change in vitamin B12 and folic acid was observed. Our findings suggest that cognitive impairment is progressively associated with duration of stay at high altitude and is correlated with elevated tHcy in the plasma. Moreover, progressive MCI at high altitude occurs despite acclimatization and is independent of vitamin B12 and folic acid.

Introduction

With the constant rise in human population at high altitude due to strategic or military reasons, athletic training or call of duty, there is a necessity to investigate the effect of prolonged exposure to high altitude on cognitive and physiological health. Studies on effect of ascent to high altitude on mountaineers show decline in physical and mental performance even on short durations of exposure lasting from few days to <05 months that is greatly influenced by rate of ascent and duration of stay at high altitude [1]. Acute exposure to decreased partial pressure of oxygen at high altitude leads to a myriad of neuro-physiological and psychological derailments including special senses such as vision, higher functions such as memory and affective behavior such as mood [2,3]. A number of studies have shown that verbal and visual short-term memory as well as recall is impaired on short duration of exposure to high altitude starting from 2500 m [4]. Moreover, there is burgeoning evidence on persistent defects in neuropsychological functions on return to sea level after brief periods of hypoxic exposure at high altitude [5]. However, considering the propositions on the onset of physiological acclimatization on prolonged stay at high altitude, the effect of chronic exposure to high altitude on cognitive performance remains to be studied.

Homocysteine, a product of methylation reactions involving transfer of methyl group from methionine in several metabolic pathways viz., DNA methylation and synthesis of coenzyme Q10, creatine, choline, epinephrine etc., has currently emerged as an independent risk factor for stroke, neurodegeneration, vascular dementia, Schizophrenia and Alzheimer’s disease [7–11]. Elevated circulating levels of total homocysteine (tHcy), has been associated with decline in cognitive performance in several geriatric population based studies [12–14]. Our previous studies have shown increase in total homocysteine (tHcy) on prolonged stay of 18 months at altitudes >4500 m [6]. However, association of tHcy in humans with cognitive performance during exposure to high altitude still remains to be investigated.

We, therefore, aimed at temporally assessing the domain specific changes in cognitive performance on different cognitive domains have been less studied. The present study aimed at investigating the time dependent changes in cognitive performance on prolonged stay at high altitude and its correlation with electroencephalogram (EEG) and plasma homocysteine. The study was conducted on 761 male volunteers of 25–35 years age who had never been to high altitude and baseline data pertaining to domain specific cognitive performance, EEG and homocysteine was acquired at altitude ≅240 m mean sea level (MSL). The volunteers were inducted to an altitude of 4200–4600 m MSL and longitudinal follow-ups were conducted at durations of 03, 12 and 18 months. Neuropsychological assessment was performed for mild cognitive impairment (MCI), attention, information processing rate, visuo-spatial cognition and executive functioning. Total homocysteine (tHcy), vitamin B12 and folic acid were estimated. Mini Mental State Examination (MMSE) showed temporal increase in the percentage prevalence of MCI from 8.17% on 03 months of stay at high altitude to 18.54% on 18 months of stay. Impairment in visuo-spatial executive, attention, delayed recall and procedural memory related cognitive domains were detected following prolonged stay in high altitude. Increase in alpha wave amplitude in the T3, T4 and C3 regions was observed during the follow-ups which was inversely correlated (r = –0.68) to MMSE scores. The tHcy increased proportionately with duration of stay at high altitude and was correlated with MCI. No change in vitamin B12 and folic acid was observed. Our findings suggest that cognitive impairment is progressively associated with duration of stay at high altitude and is correlated with elevated tHcy in the plasma. Moreover, progressive MCI at high altitude occurs despite acclimatization and is independent of vitamin B12 and folic acid.
there for 18 months. A battery of psychological tests was administered at (240 m MSL) and during the follow-ups at 03, 12 and 18 months post induction to high altitude to assess prevalence of mild cognitive impairment (MCI) and domain specific changes in cognition. Electroencephalogram (EEG) recordings were performed to correlate the observed psychological traits with electrophysiological activity of different brain regions. tHcy, Vit B₁₂ and folic acid levels were estimated at 250 m MSL during acquisition of baseline data and at 03, 12 and 18 months stay at high altitude to determine their co-relation with cognitive performance at high altitude.

Methods

Ethical clearance

The experimental design and procedures for conducting the investigation of Defence Institute of High Altitude Research (DIHAR), Leh-Ladakh, India in compliance with Indian Council of Medical Research (ICMR) guidelines. Informed written consent was obtained from all the participants who volunteered for the study. The data acquired was shared with the volunteer and archived in the institute for future reference.

Study population

This study was designed to conduct a longitudinal follow-up of a considerably large cohort to examine the temporal effect of stay at high altitude on the cognitive performance of healthy lowlander human population and its correlation with tHcy. The volunteers were individually informed about the purpose of the study, procedures to be administered and the expected outcome of the study and informed consent was obtained. 850 male participants initially enrolled for the study and baseline data was acquired at an altitude of 240 m MSL in Delhi and adjoining areas in the month of April 2009. Preliminary screening was performed based on eligibility criteria L1 comprising of age, gender, education, monthly income and medical examination. Physical examination was performed in the presence of a clinician and a medical questionnaire comprising questions related to occurrence of chronic diseases, physical and physiological ailments, heart problem, stroke, epilepsy, head injury, drug abuse, psychological disorders and general health status was administered to the participants (Table 1). The participants following L 1 screening, were screened for compliance to eligibility criteria L2 comprising of core behavioral measures (CBM) like core alcohol consumption (section A), core smoking behavior (section C), and core physical activity (section P) in accordance with WHO guidelines [15]. Beck Depression Inventory (BDI) was administered to investigate the presence of hitherto undetected depression that could influence cognitive performance and the information was verified from close acquaintance of the volunteer [16]. Lake Louise Score for acute mountain sickness (AMS) was administered to the participants on arrival and during 07 days acclimatization at high altitude to negate possible occurrence of AMS symptoms [17]. Mini Mental State Examination (MMSE) was administered to the participants during acquisition of baseline data and individuals having MMSE score <25 were excluded from the study (Table 2). Liver function test viz., serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT); kidney function test viz., blood urea nitrogen and creatinine, lipid profiling and blood glucose test were performed according to standard procedures to rule out possible influence of these parameters on the cognitive performance during baseline data acquisition (Table 2). Of the 850 volunteers who enrolled for the study, baseline data was acquired from 761 volunteers who complied to the inclusion criteria viz., between the age group of 25–35 years with no history of medical complications and neurological disorders, drug abuse, stroke, epileptic seizures, brain injury or cognitive impairment and with 10–15 years of education (Figure 1). Volunteers were inducted to high altitude in the month of May 2009. Active follow-ups were conducted at 03 months (follow-up 1, August 2009), 12 months (follow-up 2, May 2010) and 18 months (follow-up 3, November 2010) of induction to high altitude regions of Ladakh. Follow-up studies after induction to high altitude were carried out in make shift set ups in the subject locations at altitudes ranging from 4200 m–4600 m above MSL, during May 2009 to November 2010, that included remote areas in Ladakh. Similar ambience was maintained during each phase of the study to minimize influence of external environment on the cognitive test battery. Female subjects were not recruited to rule out the influence of estrogen and other hormonal factors on the results of the study.

Physiological measurements

The participants were made to relax in sitting position 05 minutes prior to acquisition of physiological data. Systolic and diastolic blood pressure (SBP and DBP), pulse rate and oxygen saturation of hemoglobin (SpO₂) were recorded in sitting position. Height and weight were measured using portable anthropometer and digital weighing machine respectively. The body mass index (BMI) was then calculated and expressed in kg/m².

Neuropsychological assessment

MCI was diagnosed following multidisciplinary meetings involving neuropsychologists, researchers and clinicians based on...
a battery of neuropsychological tests and physical examination. Neuropsychological battery was administered by trained professionals and analysis of data was performed independently by a statistician.

**MCI Screening Tests.** Subjects were screened with Mini mental State Examination (MMSE) which is a brief 30-point questionnaire for assessment of MCI [18]. Subjects obtaining score greater than and equal to 25 out of 30 were considered to be MCI. A recently designed and validated 45-point Multi Domain Cognitive Screening Test (MDCST) was also administered simultaneously to assess nine different cognitive domains (5 point for each domain) viz., orientation, memory, visuo-spatial executive, object recognition, attention, delayed recall, language, coordination and procedural memory [19]. Subjects scoring 36 and above out of 45 point scale were considered as cognitively normal participants (CNP) while scores below 36 were considered as MCI.

**Raven Standard Progressive Matrices (RSPM).** RSPM was administered to assess general intelligence and visuo-spatial cognition according to the procedure suggested by Raven et al [20]. Completion of the test queries required involvement of working memory, category shift, mental flexibility, problem solving, abstraction and reasoning. The test comprised of five sets (A to E) of 12 items each (e.g. A1 through A12), with items within a set becoming increasingly difficult and requiring greater cognitive abilities to encode and analyze information. Scoring was based on duration of completion and total number of correct attempts. All items were presented in black ink on a white background.

**Clock Drawing Test (CDT).** Visuo-spatial ability which is primarily attributed to the functioning of the parietal lobe was measured by using CDT as suggested by Schulman [21]. In brief, the participants were asked to fill in the numbers and then set the time to ‘08:20’ in a pre-drawn circle (approximately 10 cm in diameter). A score of ‘0’ implied an intact clock while score of ‘1’

---

**Table 1. Basic inclusion criteria (Eligibility criteria L1) for volunteers enrolled for the study.**

| Parameters                                      | Value       |
|------------------------------------------------|-------------|
| Age (Years)                                    | 27.3±2.34  |
| Birth altitude range (Min-Max, M, MSL)         | 213–305     |
| Duration of stay at high altitude (Years)      | 0           |
| Education (Years)                              | 12±2        |
| Income per month (INR)                         | 18000±2243  |

**Medical History/Health Status**

Any serious health illness No
Head injury resulting in loss of consciousness No
Any form of seizures, delirium tremens or convulsions No
Allergies to medication, foods, animals, chemicals or other agents No
Lung diseases such as asthma, emphysema, or chronic bronchitis No
Surgeries or hospitalizations No
Hypertensions No
Diabetes No
Viral hepatitis No
Dementia/Memory Impairment No
Stroke/Infarction/Cerebral Hemorrhage No
Kidney disease No
GERD symptoms No
Chest pain No
Congenital heart disease No
Neurological Problem/Epilepsy No
Cancer No
Heart attack or any heart problem No
Familial disorders No

---

**Table 2. Eligibility Criteria L2 comprising of core behavioral measures (CBM), Beck Depression Inventory (BDI), Mini Mental State Examination (MMSE), Lake Louise Score for Acute Mountain Sickness and baseline characteristics for kidney function, lipid profile, liver function and blood glucose.**

| Core Behavioral Measures (%) | Values       |
|------------------------------|--------------|
| Core Alcohol Consumption (Section A) | No Consumption (%) 97.7 |
|                               | Mild Consumption (%) 2.3 |
|                               | Moderate Consumption (%) Nil |
|                               | Severe Consumption (%) Nil |
| Core Tobacco Use (Section C)  | No Smoker 95.7 |
|                               | Mild Smoker (%) 4.3 |
|                               | Moderate Smoker (%) Nil |
| Core Physical Activity (Section P) | Mild (%) 82.43 |
|                               | Moderate (%) 16.52 |
|                               | Severe (%) 1.05 |
|                               | Severe Smoker (%) Nil |
| Beck Depression Inventory (BDI)(Score) | 5.23 ±1.34 |
| Mini Mental State Examination(Score) | 28.01 ±0.72 |
| Lake Louise Score | 0 |

**Biochemical Estimations**

**Kidney Function Test**

Blood Urea Nitrogen (6–20 mg/dl) 9.3±1.1
Creatinine (0.9–1.3 mg/dl) 1.01±0.11

**Lipid Profile**

Cholesterol (<=200 mg/dl) 139.9±24.1
Triglycerides (<150 mg/dl) 82.3±26.2
HDL (40–60 mg/dl) 46.5±5.3
LDL (<100 mg/dl) 81.4±12.3
Chol/HDL Ratio (<3.3) 2.95±0.28
LDL/HDL Ratio (<3.0) 1.88±0.5
VLDL (≤30 mg/dl) 16.5±5.2

**Liver Function test**

SGOT (15–37 U/L) 27.8±5.0
SGPT (30–65 U/L) 40.16±7.57

**Blood Glucose**

Fasting Glucose 83.02±3.91

Values depicted either as percentage or as Mean±SD of the study population.
doi:10.1371/journal.pone.0101448.t002
and above implied cognitive impairment. Errors like omissions of
clock hands, perseverations, rotations, misplacement of digits,
distortions, substitutions and additions were also considered during
the scoring.

Bender Visual Motor Gestalt Test (BGT). BGT was
administered to determine visual motor maturity and motor skills
[22,23]. The test consisted of nine figures on a 3 × 3 dimensioned
card. Each figure was shown to the subjects who were asked to
copy them onto a piece of blank paper and scoring was done using
Hain's method. Errors were counted on the basis of 15 different
signs like perseveration, rotation, concretism, added angles,
separation of lines, overlap, embellishment, partial rotation,
omission, abbreviation, separation, absence or erasure, closure
and point of contact. Each sign was scored only once and the final
score was calculated. The total error score ranged from 0–34.

Serial Digit Learning Test (SDLT). SDLT comprised of a
9-digit series presented orally to the participants at the rate of 1
digit per second, and the participants were asked to learn and
repeat them in their given order [24]. The procedure was
terminated if the participant repeated the series correctly in two
consecutive trials or when the participant could not repeat the
series in 12 consecutive trials. The performance on SDLT
required utilization of mnemonic strategies and this test therefore,
served as a tool for assessing attention, learning and memory.

Stroop Color Word Interference Test-TBAG Form
(SCWT). SCWT was administered according to the procedure
suggested by MacLeod to assess the information processing rate,
parallel processing of attended and unattended stimuli and
attention [25]. There was no time limit to complete a subtask.
The time needed to complete each Stroop subtask served as
dependent measures (Stroop I, Stroop II, and Stroop III
respectively). The examiners did not point out errors made during
the test and participants spontaneously corrected themselves if
they noticed an error. The number of errors that were not self
corrected was also recorded for each Stroop subtask (Error I, Error
II and Error III respectively). Poor performance was marked by
higher inference score in this test.

Trail Making Test (TMT). TMT was administered to assess
visual search speed, scanning, speed of processing, mental
flexibility, attention as well as executive functioning. TMT was
bifurcated into two parts: TMT-A required an individual to draw
lines sequentially connecting 25 encircled numbers distributed in
ascending sequential order on a sheet of paper until he reached the
circle labeled ‘END’. TMT-B comprised of circled alphabets
ranging from A to L and 1–13 and the participant was asked to
circle labeled ‘END’. TMT comprised of circled alphabets
ranging from A to L and 1–13 and the participant was asked to
alternate between numbers and letters (e.g., 1, A, 2, B, 3, C, etc.) in
ascending sequential order until he reached the circle labeled
‘END’. The time required to complete the test was considered as
the test score [26].

Verbal Fluency Test (VFT). VFT was performed to evaluate
the executive function of the frontal and temporal lobe.
Participants were asked to say as many words as possible from a
category (e.g., birds, animals etc.) in a given time (60 seconds).
Higher value of score in this test was dependent on the number of
words named by the subject in the given time [27].

EEG data acquisition and analysis
Electrodes were placed according to the universal 10–20 system
and the electroencephalogram (EEG) signals were recorded from
electrodes placed on scalp positions viz. frontal (Fp1, Fp2), central
(C3, C4), temporal (T3, T4) and occipital (O1 and O2) sites using
Neurotravel EEG System (ATES medica Device, Verona, Italy).
Subjects were made to relax in sitting position for five minutes
following which EEG signal was recorded with closed eyes for ten
minutes. The EEG was recorded with a 0–30 Hz bandpass and
digitized using a 500 Hz sampling rate. EOG and EMG signals
were also recorded to remove artifacts due to eye and muscle
movements during signal processing. The algorithm for digital
signal processing used a 1024 point Fast Fourier Transform with
Hamming windows (−33 dB stop band, filter degree 1068,
transition bandwidth 0.622 Hz, in 30 s block. Amplitude analysis
was done for all the frequency bands employing Neurotravel map
software (V2.5.2.26, ATES medica device, Verona, Italy) after
eliminating different motion artifacts. Continuous EEG raw signal
was divided into epochs of 30 seconds and independent
component analysis was applied to remove eye blinks and muscle
artifacts.

Biochemical estimations
Blood was collected from the volunteers in aseptic conditions by
venous puncture after an overnight fast. The tHcy levels in plasma
was determined using high pressure liquid chromatography
(HPLC) (Waters, Milford, MS, USA) according to the procedure
suggested by Refsum et al. [28]. System detectors were adjusted
for excitation of 385 nm and an emission of 515 nm to capture
fluorescence separated compounds. tHcy was estimated from a
calibration curve obtained from known amounts of homocysteine
[28]. Serum was extracted from blood samples by centrifugation at
6000 rpm for 5 minutes. Serum levels of folic acid and vitamin B12
were determined by a radio assay kit (Bio-Rad, Richmond, CA),
according to the manufacturer’s instructions. The concentration of
vitamin B12 and folic acid in serum was determined by
extrapolation from the standard curve.

Statistical analysis
The participants were categorized into two separate sub groups
viz. CNP and MCI based on their psychological scores with
respect to globally accepted normal values. Descriptive analysis
was done for the psychological scores. Mean, standard deviation
and standard error of mean was calculated for each group.
Statistical analysis was performed using ANOVA with Duncan’s
Post Hoc test for comparisons between groups using SPSS 17.0
Statistic software (SPSS, Chicago, IL, USA). Relations between
variables were analyzed by calculating the Pearson product-
moment correlation coefficients. P-values <0.05 (two tailed) were
considered to be significant. The data was archived in the central
records keeping centre of DIHAR.

Results
Physiological characteristics of the study population
Physiological tests (Table 3) were performed at baseline before
induction and during all the follow-ups. Simple t-test was done
between baseline and follow-up recordings independently. Oxygen
saturation was found to be low during all the follow-ups conducted
at high altitude (P<0.05) when compared to baseline values.
Systolic and diastolic blood pressure was within physiological
range, though a significant change in pulse rate was observed
during the follow-ups at high altitude. No change in waist/hip
ratio and BMI was observed during the study period.

Neuropsychological changes on prolonged stay at high
altitude
Table 4 depicts the mean MMSE and MDCST scores of the
study population at baseline and during the follow-ups. The results
showed significant decrease in the mean MMSE score indicating
increase in MCI during second (24.2±0.84, P<0.05) and third
(24.4±0.45, P<0.05) follow-up when compared with the baseline
scores (28.2±0.27). As indicated in figure 2, there was a persistent
temporal increase in the percentage prevalence of MCI that
ranged from 8.17% in the first follow-up, to 12.46% in the second
follow-up and further increasing up to 18.54% during the third
follow-up as determined by MMSE (figure 2). The visuo-spatial
executive, attention and problem solving domains were most
affected during stay at high altitude and the decline was
progressive as shown in Table 4. Considerable decline in delayed
recall and procedural memory functions was also observed during
the second (P<0.05) and third follow-ups (P<0.05). Derailment in
orientation was observed only during the third follow-up when
compared with baseline CNP. Individuals showing cognitive
delay in any of the affected domains did not revert back to
normal during the period of investigation. One-way ANOVA of
the data of RSVP test revealed a significant difference in response
values between the baseline (41.03±7.65) and the follow-ups
(65.01±10.03 for follow-up 1, 67.9±9.3 for follow-up 2, and
69.81±6.93 for follow-up 3, P<0.05) as shown in Table 4. One-
way ANOVA with repeated measures also detected a significant
difference in CDT values of the baseline and the follow-ups (P<
0.05). An intact clock carrying score ‘0’ was obtained by the CNPs
during follow-ups. Significant increase in CDT scores of MCI was
observed during first (1.93±0.39, P<0.05) and second (2.17±0.21,
P<0.05) follow-up due to the errors like misplacement of digits,
distortions, substitutions and additions. Errors like omissions of
clock hands, perseverations, and rotations contributed to increase
in CDT scores during third follow-up (2.30±0.51, P<0.05).

Consecutive trial was taken as the variable in the SDLT, a
measure of attention, where the scores were found to decrease
significantly in MCI group during the follow-ups (5.19±3.12, for
follow-up 1, 6.53±4.07, for follow-up 2, and 5.07±3.81, for
follow-up 3, P<0.05). No difference in scores of learn and repeat
task of SDLT was observed between the baseline and CNP during
follow-ups (14.83±4.12, for baseline, 12.97±5.47, for follow-up 1,
14.38±3.17, for follow-up 2, and 15.03±4.21, for follow-up 3, P>
0.05). However, response duration in Stroop III of SCWT
increased in MCI during the follow-ups. One-way ANOVA revealed
significant delay in response between baseline and MCI
during follow-ups in the Stroop III (69.41±9.72, for follow-up 1,
73.19±12.71, for follow-up 2, and 71.28±14.26, for follow-up 3,
P<0.05). A difference in language ability over the entire reading
and learning sequences was observed only at third follow-ups
(0.98±0.73, P<0.05). No significant change in scores of MCI was
observed during first (2.47±0.79, P>0.05) and second (2.79±0.81,
P>0.05) follow-up due to less errors.

Electrophysiological changes at high altitude
Analysis of EEG data acquired from the participants in eyes
closed position for theta wave amplitude showed decrease in the
T3 region (95% CI 9.82–13.44) but a corresponding increase in the
T4 region (95% CI 17.95–21.49) following 3 months of
induction to altitude. On the contrary, there was an increase in
alpha wave amplitude in the T3 (95% CI 17.43–19.63), T4 (95% 
CI 18.83–21.2) and C3 (95% CI 20.78–22.46) regions. In
addition, a strong inverse correlation (r = −0.68) was observed
between alpha wave amplitude and both MMSE and MDCST
scores. In addition to the decreased theta wave amplitude in the
T3 region (95% CI 9.44–11.82) and increased amplitude in T4
region (95% CI 21.52–22.84) and increased alpha wave amplitude
in the T3 (95% CI 20.93–22.84), T4 (95% CI 20.30–22.44) and
C3 (95% CI 21.87–23.95) region, we also observed an increase in
alpha wave amplitude in the C4 region (95% CI 22.03–25.65)
along with decrement in beta wave amplitude in the T3 (95% CI
9.44–11.82) and T4 (95% CI 9.44–11.82) regions (Table 5).
Interestingly, on prolonged stay at high altitude for 18 months, no
change in theta and beta wave amplitude was observed as shown
in figure 3. The alpha wave amplitude however continued to
remain high in all the regions of interest when compared to the
baseline values as shown in (Table 5).

Association of biochemical parameters with MCI

The box plots in figure 4 depict the biochemical profile of tHcy,
vitamin B12 and folate acid showing progressive increase in the

---

**Table 3. Physiological Characteristics at baseline and during different durations of stay at high altitude.**

| Parameters | Baseline | Follow-up 1 (After 3 months) | Follow-up 2 (After 12 months) | Follow-up 3 (After 18 months) |
|------------|----------|-----------------------------|------------------------------|------------------------------|
| SpO₂ (%)   | 97.40±0.62 | 89.03±0.51                  | 91.24±0.39                   | 91.31±0.59                   |
| PULSE RATE | 77.18±1.54 | 80.64±0.97                  | 80.50±1.87                   | 82.5±2.29                    |
| W/H Ratio  | 0.90±0.04  | 0.89±0.03                   | 0.88±0.06                    | 0.89±0.08                    |
| BMI        | 23.13±1.30 | 23.46±1.61                  | 21.86±1.37                   | 21.13±1.14                   |
| SBP (mm Hg)| 120±1.23  | 122±1.83                    | 122±1.75                     | 121±1.77                     |
| DBP (mm Hg)| 81±1.01   | 83±2.18                     | 82±1.60                      | 82±1.13                      |

Values depict Mean±SEM, *denotes P<0.05 when compared to baseline values.

doi:10.1371/journal.pone.0101448.t003

---

**Figure 2. Percentage prevalence of mild cognitive impairment in study population during baseline and follow-ups.** Percentage of participants with mild cognitive impairment (MCI) increased progressively with duration of stay at high altitude.
doi:10.1371/journal.pone.0101448.g002
Table 4. Assessment of cognitive impairment using Mini Mental State Examination (MMSE), Multi Domain Cognitive Screening Test (MDCST), Raven Standard Progressive Matrices (RSPM), Clock Drawing Test (CDT), Bender Visual Motor Gestalt Test (BGT), Facial Recognition Test (FRT), Serial Digit Learning test (SDLT), Stroop Color Word Interference Test-TBAG Form (SCWT), Verbal fluency test (VFT), Visual-aural digit span test-B (VADS-B) during baseline and follow-ups.

| PARAMETERS | Baseline (n = 761) | Follow up 1 (n = 758) | Follow up 2 (n = 744) | Follow up 3 (n = 727) |
|------------|---------------------|------------------------|------------------------|------------------------|
|            | CNP (n = 696) | MCI (n = 62) | CNP (n = 651) | MCI (n = 93) | CNP (n = 592) | MCI (n = 135) |
| MMSE       | 27.20 ± 0.27     | 25.20 ± 0.62          | 28.40 ± 0.92          | 24.20 ± 0.84          | 28.00 ± 0.52          | 24.40 ± 0.45 |
| MDCST      | 38.63 ± 2.87     | 32.63 ± 1.73          | 37.43 ± 2.04          | 30.70 ± 2.87          | 38.37 ± 1.82          | 28.01 ± 3.07 |
| Orientation| 4.50 ± 0.49      | 4.13 ± 0.00           | 4.26 ± 0.69           | 4.10 ± 0.88           | 4.55 ± 0.51           | 3.19 ± 0.81  |
| II. Visuospatial Executive | 3.98 ± 0.97 | 2.13 ± 0.41          | 3.78 ± 0.90           | 2.20 ± 0.48           | 3.79 ± 0.90           | 2.00 ± 0.25  |
| III. Attention & problem solving | 4.53 ± 0.88 | 3.47 ± 0.28          | 4.57 ± 0.79           | 3.40 ± 0.39           | 4.41 ± 0.56           | 3.16 ± 0.27  |
| IV. Memory Registration & immediate recall | 4.78 ± 0.48 | 4.54 ± 0.28          | 4.87 ± 0.34           | 4.80 ± 0.42           | 5.00 ± 0.00           | 4.58 ± 0.42  |
| V. Object recognition & remote memory | 4.83 ± 0.38 | 5.00 ± 0.00          | 4.83 ± 0.39           | 4.80 ± 0.42           | 4.83 ± 0.38           | 4.95 ± 0.23  |
| VI. Mind Body Coordination and Learning | 3.85 ± 1.42 | 3.33 ± 0.58          | 3.91 ± 0.85           | 2.60 ± 0.97           | 3.24 ± 0.79           | 1.95 ± 1.08  |
| VII. Language | 3.60 ± 1.15 | 2.74 ± 1.00          | 3.43 ± 0.95           | 2.90 ± 1.45           | 3.69 ± 1.14           | 2.95 ± 1.22  |
| VIII. Delayed Recall | 4.70 ± 0.30 | 4.00 ± 1.00          | 4.00 ± 0.95           | 3.40 ± 0.37           | 4.21 ± 0.94           | 3.13 ± 0.30  |
| IX. Procedural Memory | 4.88 ± 0.22 | 4.64 ± 0.24          | 4.78 ± 0.28           | 3.50 ± 0.44           | 4.59 ± 0.32           | 2.89 ± 0.54  |
| VISUO SPATIAL ABILITY |        |                   |                       |                       |                       |               |
| RSPM       | 41.03 ± 7.65     | 65.01 ± 10.03        | 43.84 ± 9.13          | 67.8 ± 9.30           | 40.61 ± 5.72          | 69.81 ± 6.93 |
| BGT        | 1.21 ± 0.92      | 1.87 ± 1.01          | 1.08 ± 0.79           | 1.04 ± 0.74           | 1.92 ± 1.27           | 1.51 ± 1.07  |
| CDT        | 0                | 1.93 ± 0.39          | 0                     | 2.17 ± 0.21           | 0                     | 2.30 ± 0.51  |
| ATTENTION  |                   |                       |                       |                       |                       |               |
| SDLT       | 14.83 ± 4.12     | 5.19 ± 3.12          | 14.38 ± 3.17          | 6.53 ± 4.07           | 15.03 ± 4.21          | 5.07 ± 3.81  |
| SCWT       | 32.83 ± 11.07    | 69.41 ± 9.72         | 33.71 ± 10.86         | 73.19 ± 12.71         | 30.51 ± 11.09         | 71.28 ± 14.26 |
| Trail making Test PART A | 22.13 ± 6.03 | 23.21 ± 7.47        | 24.91 ± 8.34          | 28.49 ± 7.51          | 21.37 ± 6.57          | 20.67 ± 6.39 |
| Trail making Test PART B | 43.71 ± 8.21 | 41.52 ± 6.39        | 40.82 ± 5.70          | 38.64 ± 7.48          | 40.36 ± 6.31          | 39.72 ± 6.92 |
| MEMORY AND LANGUAGE ABILITY |        |                   |                       |                       |                       |               |
| VFT-Birds  | 17.56 ± 2.81     | 17.28 ± 3.18         | 17.53 ± 4.72          | 18.94 ± 3.85          | 18.71 ± 5.03          | 17.27 ± 2.93 |
| VFT-Animals| 28.51 ± 3.62     | 25.93 ± 3.75         | 28.39 ± 4.76          | 27.21 ± 2.21          | 25.01 ± 7.03          | 26.54 ± 3.73 |

Value depicts Mean ± SD.
* denotes P-value < 0.05 when compared to baseline data.
doi:10.1371/journal.pone.0101448.t004
prevalence of hyperhomocysteinemia in the study population. The results showed elevated mean tHcy levels in all the follow-ups (13.54 ± 2.46, \( P < 0.05 \) for first follow-up, 16.29 ± 5.42, \( P < 0.05 \) for second follow-up and 21.42 ± 3.74, \( P < 0.001 \) for third follow-up), when compared with baseline CNP (8.64 ± 0.76). No significant change was observed in the serum vitamin B12 and folic acid levels during the follow-ups (\( P > 0.05 \)). Table 6 illustrates Pearson’s correlation between MMSE score and plasma tHcy, serum vitamin B12 and serum folic acid. tHcy levels in all the three follow-ups showed a progressive positive association with MCI when compared to the baseline CNP. Plasma levels of tHcy were inversely correlated with MMSE score in all the follow-ups (\( r = -0.431; \ P < 0.001 \) for first follow-up, \( r = -0.345; \ P < 0.05 \) for second follow-up, and \( r = -0.838; \ P < 0.001 \) for third follow-up). No significant correlation was found between MMSE score and vitamin B12 or folic acid.

Discussion

High altitude is characterized by a decrease in partial pressure of oxygen leading to reduced oxygen saturation of blood and stunted oxygen availability to the tissues resulting in a physiological condition called hypobaric hypoxia [1,3,6]. The brain, in particular, is known to be most susceptible to oxygen deficiency. Despite the fact that a considerable size of low lander human population stay at high altitude for long durations due to occupational requirements, the effect of hypobaric hypoxia on cognition of these individuals has not been adequately understood. In this prospective study of 761 healthy non-demented low lander population with normal MMSE and MDCST scores who were inducted to high altitude environment of 4200–4600 m for 18 months due to occupational requirements, there was an irreversible duration dependent increase in prevalence of MCI that was correlated with duration of stay at high altitude. Assessment of cognitive domains using Mini mental State Examination and neuropsychological battery comprising of Multi Domain Cognitive Screening Test, Raven Standard Progressive Matrices, Clock Drawing Test, Bender Visual Motor Gestalt Test, Serial Digit Learning test, Stroop Color Word Interference Test-TBAG Form, Trail Making Test and Verbal Fluency Test showed impairment in visuo-spatial executive, attention, delayed recall and procedural memory related cognitive domains.

Previous reports on effect of hypobaric hypoxia on human physiology suggest occurrence of acclimatization after 3–5 days of induction to high altitude. Onset of acclimatization is considered to be an outcome of physiological adjustments to the hypobaric conditions at high altitude for evading the deleterious effects of oxygen deficiency [29]. Our findings, however, reveal that despite physiological acclimatization, prolonged stay at high altitude results in derailment of cognitive performance in sea level natives. The domain specific assessment of prospective cognitive decline at high altitude revealed early onset of deficits in visuo-spatial executive and attention while decline in cognitive domains related to delayed recall and procedural memory were observed only after 12 months of stay at high altitude. Assessment by RSPM showed a derailment in executive functioning on prolonged stay while decrease in scores of CDT test indicates derailment of constructive praxis, indicating altered function of parietal lobe. Increase in SDLT and decrease in SCWT scores following stay at high altitude indicated towards alteration in medial temporal lobe, hippocampus and frontal lobe activity resulting in decreased attention. Though no detectable change was observed in the memory domain on 03 months and 12 months of stay at high altitude as assessed by verbal fluency test, decline in comprehension was observed following 18 months stay indicating that long term memory impairment onsets on longer durations of stay at high altitude. These findings are in agreement with previous reports by Zhang et al (2011) reporting impairment in immediate recall following stay for 06 months at an altitude of 2260 m [30]. However, contrary to the findings on minimal effect of high altitude on long term memory, we observed a decline in language and comprehension on prolonged stay of 18 months at 4200 m. This discrepancy may be attributed to the higher altitude and longer duration of stay in hypobaric conditions during the present study.

Figure 3. Representative brain maps of alpha, beta and delta components of EEG of the same participant during baseline and follow-ups. Scale bar shows regional activity in mkV. doi:10.1371/journal.pone.0101448.g003
Table 5. Amplitudes (μV) of EEG wave components at different electrode positions.

| ROI | Wave | Baseline | | | Followup 1 | | | Followup 2 | | | Followup 3 | | |
|-----|------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|     |      | Normal   | MCI      |          | Normal   | MCI      |          | Normal   | MCI      |          | Normal   | MCI      |          |
| T3  | Delta| 41.44±1.61| NA       |          | 41.28±1.88| 39.63±2.05|          | 40.12±0.51| 41.59±1.71|          | 41.13±1.35| 39.31±0.41|          |
|     | Theta| 14.23±2.23| NA       |          | 15.14±1.33| 11.63±1.81|          | 14.11±0.75| 10.63±1.19|          | 14.31±1.07| 13.6±1.72 |          |
|     | Alpha| 15.11±1.73| NA       |          | 16.21±1.02| 18.53±1.1  |          | 14.23±1.92| 21.91±0.93|          | 15.71±1.91| 24.79±1.8 |          |
|     | Beta | 6.62±1.84 | NA       |          | 7.78±1.12 | 6.94±0.58 |          | 6.18±1.92 | 4.09±0.58 |          | 6.41±0.4  | 5.93±1.12 |          |
| T4  | Delta| 45.8±1.43 | NA       |          | 41.15±1.31| 40.13±0.39|          | 38.12±1.91| 40.18±0.49|          | 41.06±1.05| 39.01±1.01|          |
|     | Theta| 14.68±1.00| NA       |          | 15.35±1.32| 19.72±1.77|          | 15.41±1.41| 21.19±1.62|          | 15.98±1.51| 16.65±2.67|          |
|     | Alpha| 14.56±1.97| NA       |          | 16.16±1.37| 20.02±1.19|          | 15.01±1.3 | 21.37±1.07|          | 15.22±0.93| 23.14±1.33|          |
|     | Beta | 6.45±1.89 | NA       |          | 6.2±1.5  | 6.4±1.13  |          | 6±0.9| 4.4±0.23|          | 5.5±1.92 | 5.01±0.92 |          |
| C3  | Delta| 39.4±1.74 | NA       |          | 39±1.23  | 38.1±0.92 |          | 39.14±1.21| 39.06±0.9 |          | 36.09±1.67| 37.08±1.07|          |
|     | Theta| 14.17±1.04| NA       |          | 14.99±1.47| 13.89±1.92|          | 15.16±1.7 | 14.09±1.01|          | 14.01±0.75| 14.89±1.57|          |
|     | Alpha| 16.63±1.64| NA       |          | 15.14±1.08| 21.62±0.84|          | 15.21±0.68| 22.91±1.04|          | 16.23±1.09| 21.03±1.00|          |
|     | Beta | 6.7±1.62 | NA       |          | 6.3±1.11 | 6.00±1.92 |          | 6.03±1.39 | 5.9±0.93 |          | 6.89±1.08 | 5.08±1.33 |          |
| C4  | Delta| 39.33±1.05| NA       |          | 38.13±2.01| 40.61±1.41|          | 39.49±1.24| 39.73±1.01|          | 41.09±1.17| 38.53±1.25|          |
|     | Theta| 13.19±1.73| NA       |          | 12.71±1.59| 11.93±2.84|          | 13.11±1.04| 12.19±1.21|          | 13.74±1.42| 12.04±1.09|          |
|     | Alpha| 16.34±1.96| NA       |          | 16.05±1.03| 19.91±2.42|          | 15.35±1.03| 23.59±1.81|          | 14.76±1.23| 21.06±1.19|          |
|     | Beta | 6.2±1.24 | NA       |          | 6.7±1.38 | 6.18±1.39 |          | 6.79±1.34 | 6.58±0.99 |          | 5.17±1.79 | 6.17±1.82 |          |

Value depicts mean ± SEM.
*denotes P-value <0.001 when compared to baseline values. ROI: region of interest.
doi:10.1371/journal.pone.0101448.t005
Contradictory to reports on restoration of cognitive performance following acclimatization, the impairment in the cognitive domains was irreversible during the entire period of our study [31]. Our results, however, find support from reports of “Everest-Comex 97” during which climbers participating in a simulated climb from sea level to 8,848 m over a 31 day period showed selective impairment of mental learning processes related to cortico-limbic system rather than basal ganglia-sensorimotor system function [32]. Similar attentional changes in a group of volunteers staying at an altitude of 6,542 m for 21 days has also been previously reported [5]. Reports on MRI scans also showed abnormalities in several brain areas and occurrence of cortical atrophy following ascent to high altitude [33,34].

In addition to assessing the psychological changes associated with cognition, we also attempted to determine the electrophysiological correlates for the observed psychological changes. This is probably the first report on increase in alpha wave amplitude on prolonged stay of acclimatized low landers at high altitude for 18 months that in turn is positively correlated with MCI. Our study finds support from previous reports that show increase in P300 latency suggesting that hypoxia causes slowing of the signal processing at 4300 m, and magnitudes of the effects are altitude dependent [33]. The P300 (P3) wave is an event related potential component elicited in the process of decision making and is linked to a person’s reaction time in response to stimuli. However, most of the studies on effect of hypobaric hypoxia on electrophysiological activity of the brain have been conducted on small cohorts with the duration of stay ranging from a few days to 3 months.

The present study also provides evidence for elevation in tHcy which was positively correlated to MCI and duration of stay at high altitude. Consistent to our previous report, the tHcy levels at high altitude were independent of serum vitamin B12 and folic acid levels which were in the normal range in all the participants of the study [6]. The optimal concentration of serum vitamin B12 and folic acid in the study population during the follow-ups at high altitude could be attributed to the administration of healthy diet recommended at high altitude. Though several studies have focused on hematological and metabolic effects of hypoxic exposure, no study has been conducted on the correlation of cognitive performance at high altitude with tHcy [36,37]. However, increase in circulatory homocysteine has been previously reported in chronic stress models and age related neurological disorders [8]. The positive correlation between tHcy and MCI scores that was observed during the present study finds support from reports on association of hyperhomocysteinemia with cognitive decline in several neurodegenerative disorders including Multiple Sclerosis, Parkinson’s disease and Alzheimer’s disease [38]. Higher white matter lesion in atherosclerotic disease has also been attributed to hyperhomocysteinemia [39]. Considering previous reports on reduced white matter in motor function areas of the brain and occurrence of sagittal sinus thrombosis following ascent to high altitude, elevated homocysteine at high altitude...
could certainly play a key role in the psychological and pathophysiological manifestations of low oxygen in the brain functions [40,41].

The present study, to the best of our knowledge, is the first report on association of hyperhomocysteinemia with decrease in cognitive performance at acclimatized sea level natives on prolonged stay for 18 months at high altitude. Besides that, considering the role of homocysteine in cardio-vascular as well as aging associated neurological disorders, our findings on occurrence of hyperhomocysteinemia on longer duration of stay at high altitude could be of considerable clinical relevance for occupational health at high altitude.

Homocysteine is metabolized either through the re-methylation pathway, which regenerates methionine through a folic acid mediated mechanism or the trans-sulfuration pathway that degrades homocysteine into cysteine and requires vitamin B6 [7]. Cysteine in turn is a precursor for synthesis of reduced glutathione (GSH) which is a major cellular antioxidant. Our previous studies have shown increase in oxidative stress and depletion in GSH following exposure to high altitude [42]. Since the increase in tHcy during the present study was independent of vitamin B12 and folic acid concentrations and increase in tHcy could have both protective effect by augmenting the antioxidant status as well as deleterious effect by mediating neurodegeneration, further investigations on metabolic pathways leading to increased homocysteine synthesis or reduced clearance may provide an insight into the biochemical changes occurring at high altitude. A major strength of the present study lies in the association of hyperhomocysteinemia with cognitive decline at high altitude which could be used for clinical diagnosis of MCI and provide valuable information on the health of the brain at high altitude. The findings of the present study also contradict the popular notion of acclimatization by revealing the duration dependent decrease in cognitive impairment at extreme altitudes, thereby necessitating investigations to understand the effect of chronic hypobaric hypoxia on the brain functions and metabolism.

Conclusions

The findings of the present study indicate towards progressive mild cognitive impairment in acclimatized lowlanders on prolonged stay at high altitude. The mild cognitive impairment observed at high altitude is associated with increase in alpha wave amplitude and is correlated with hyperhomocysteinemia. These findings could have considerable clinical significance in diagnosis of mild cognitive impairment and assessment of cognitive health in high altitude conditions.

Acknowledgments

We are greatly indebted to all the participants for their whole hearted cooperation despite the extreme climatic conditions in Ladakh and without whose support we could not have successfully completed the study. The study was financially supported by Defence Research and Development Organization, Government of India. We also acknowledge the guidance, help and support of Dr Shashi Bala Singh for conducting the study.

Author Contributions

Conceived and designed the experiments: VKS KBH SKH. Performed the experiments: VKS SKD PD KBH SKH TN AK. Analyzed the data: BBM TN SKH VV. Contributed reagents/materials/analysis tools: SKH RBS TN. Wrote the paper: VKS SKD KBH VV SKH. Concise review of manuscript: RBS TN SKH.

References

1. Singh SB, Thakur L, Anand JP, Yadav D, Amitab, et al. (2004) Effect of chronic hypobaric hypoxia on components of the human event related potential. Indian J Med Res 120: 94–9.
2. Regard M, Oelz O, Brugger P, Landis T (1989) Persistent cognitive impairment in climbers after repeated 10-day exposure to extreme altitude. Neurology 39: 210–5.
3. Shukitt-Hale B, Stillman MJ, Welch DI, Levy A, DeVine JA, et al. (1994) Hypobaric hypoxia impairs spatial memory in an elevation-dependent fashion. Behav Neural Biol 62: 244–52.
4. West JB (1986) Lactate during exercise at extreme altitude. Fed Proc 45: 2953–7.
5. Bonnon M, Noé ¨l-Jorand MC, Therme P (2000) Effects of different stay durations on attentional performance during two mountain expeditions. Aviat Space Environ Med 71: 678–84.
6. Tu MC, Huang CW, Chen NC, Chang WN, Lui CC, et al. (2010) Hyperhomocysteinemia in Alzheimer dementia patients and cognitive decline after 6 months follow-up period. Acta Neurol Taiwan 19: 168–77.
7. Miller AL, Kelly GS (1997) Homocysteine Metabolism: Nutritional Modulation and Impact on Health and Disease. Alternative Medicine Review 2: 234–254.
8. Sudhuth TL, Powell DK, Smith CD, Greenstein, A, Wilcock DM (2013) Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. J Cereb Blood Flow Metab 33: 701–15.
9. Morris MS (2012) The role of B vitamins in preventing and treating cognitive impairment and decline. Adv Nutr 3: 801–12.
10. Carro M, Gugliandolo A, Gangemi C, Ristano R, Lenile R, et al. (2014) Toxic Effects of Mildly Elevated Homocysteine Concentrations in Neuronal-Like Cells. Neurochem Res [In press].
11. Kinoshita M, Numata S, Tajima A, Shimodera S, Imoto I, et al. (2013) Plasma total homocysteine is associated with DNA methylation in patients with schizophrenia Epigenetics. 8: 584–90.
12. Wright CB, Lee HS, Paik MC, Stabler SP, Allen RH, et al. (2004) Total homocysteine is associated with DNA methylation in patients with schizophrenia Epigenetics. 8: 584–90.
13. Siuda J, Gorzkowska A, Patalong-Ogiewa M, Krzystanek E, Czepczuk E, et al. (2009) From mild cognitive impairment to Alzheimer’s disease-influence of homocysteine, vitamin B12 and folic acid on cognition over time, results from one-year follow-up. Neurol Neurochir Pol 43: 321–9.
14. Vidal JS, Dufouil C, Ducros V, Tzourio C (2008) Homocysteine, folate acid and cognition in a large community-based sample of elderly people—the 3C Dijon Study. Neuroepidemiology 30: 207–14.

15. World Health Organization, Switzerland (2008) WHO STEPS. Surveillance. Available: www.who.int/chp/steps. Accessed 2008 Aug 12.

16. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–71.

17. Roach RC, Bartsch P, Odz O, Hackett PH, Lake Louise AMS Scoring Consensus Committee (1993) The Lake Louise acute mountain sickness scoring system. In: Sisson JR, Houston CS, Coates G, editors. Hypoxia and Molecular Biology. Burlington: Queen City Press. pp. 272–274.

18. Folstein MF, Robins LN, Helzer JE (1983) The Mini-Mental State Examination. Arch Gen Psychiatry 40: 812–13.

19. Hota SK, Sharma VK, Hota K, Das S, Dhar P, et al. (2012) Multi-Domain Cognitive Screening Test for neuropsychological assessment for cognitive decline in acclimatized lowlanders staying at high altitude. Indian J Med Res 136: 411–20.

20. Raven JC, Court JH, Raven J (1992) Manual for Raven’s standard progressive matrices. Oxford: Oxford Psychologists Press.

21. Schulman KI (2000) Clock-drawing, is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15: 548–61.

22. Bender L (1938) A visual-motor Gestalt test and its clinical use. American Orthopsychiatric Association Monograph Series Number 3. New York: American Orthopsychiatric Association.

23. Margolis RB, Williger NR, Greenhief CL, Dunn EJ, Gfeller JD (1989) The sensitivity of the Bender-Gestalt Test as a screening instrument for neuropsychological impairment in older adults. J Psychol 123: 179–86.

24. Karakas HM, Karakas S (2006) Learning of serial digits leads to frontal activation in functional MR imaging. Diagn Interv Radiol 12: 9–13.

25. MacLeod CM (1991) Half a century of research on the Stroop effect, an integrative review. Psycholl Bull 109: 163–203.

26. Barncord SW, Wanlass RL (2001) The symbol trail making test, test development and utility as a measure of cognitive impairment. Appl Neuropsychol 8: 99–103.

27. Lezak MD (1995) Neuropsychological assessment. 3rd ed. New York: Oxford University Press.

28. Refsum H, Ueland PM, Nygård O, Vollset SE (1998) Homocysteine and cardiovascular disease. Annu Rev Med 49: 31–62.

29. Peng QQ, Basang Z, Cui GY, Li L, Qian J, et al. (2013) Physiological responses and evaluation of effects of BMI, smoking and drinking in high altitude acclimatization: a cohort study in Chinese Han young males. PLoS One 8: 11.

30. Zhang J, Liu H, Yan X, Weng X (2011) Minimal effects on human memory following long term living at moderate altitude. High Alt Med Bio 12: 37–43.

31. Lefflen D, Poquin D, Savourey G, Barraud PA, Raphael C, et al. (1997) Cognitive performance during short acclimation to severe hypoxia. Aviat Space Environ Med 68: 993–7.

32. Abramini JH, Bouquet G, Joucla F, Nicolas M, Kriem B (1998) Cognitive performance during a simulated climb of Mount Everest, implications for brain function and central adaptive processes under chronic hypoxic stress. Pflugers Arch 436: 553–9.

33. Fayad N, Modrego PJ, Morales H (2006) Evidence of brain damage after high-altitude climbing by means of magnetic resonance imaging. Am J Med 119: 168.

34. Garrido E, Segura R, Capdevila A, Aldon J, Rodriguez FA, et al. (1995) New evidence from magnetic resonance imaging of brain changes after climbs at extreme altitude. Eur J Appl Physiol Occup Physiol 70: 877–81.

35. Singh SB, Thakur I, Anand JP, Panjwani U, Yadav D, et al. (2003) Effect of high altitude HA on event related brain potentials. Indian J Physiol Pharmacol 47: 52–8.

36. Yelmen N, Ozlemir S, Guner I, Toplan S, Sahin G, et al. (2011) The effects of chronic long-term intermittent hypobaric hypoxia on blood rheology parameters. Gen Physiol Biophys 30: 389–95.

37. Wheatley K, Creed M, Mellor A (2011) Hematological changes at altitude. JR Army Med Corps 157: 30–42.

38. Obeid R, McCaddon A, Herrmann W (2007) The role of hyperhomocysteineemia and B-vitamin deficiency in neurological and psychiatric diseases. Clin Chem Lab Med 45: 1590–606.

39. Kloopenborg RP, Nederkoorn PJ, van der Graaf Y, Geerlings MI (2011) Homocysteine and cerebral small vessel disease in patients with symptomatic atherosclerotic disease. The SMART-MR study. Atherosclerosis 216: 461–6.

40. Di Paola M, Bozzali M, Fadda L, Musicco M, Sabatini U, et al. (2008) Reduced oxygen due to high-altitude exposure relates to atrophy in motor-function brain areas. Eur J Neuro 13: 1050–7.

41. Skaita SC, Steve H (2006) Recurrent sagittal sinus thrombosis occurring at high altitude during expeditions to Cho Oyu. Wilderness Environ Med 17: 132–6.

42. Hota SK, Barhwal K, Singh SB, Ilavazhagan G (2007) Differential temporal response of hippocampus, cortex and cerebellum to hypobaric hypoxia: a biochemical approach. Neurochem Int 51: 304–90.